TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10680107
Drug: Cisatracurium 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.025 mg/kg (0.5 x ED95)
Study: 8765865
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml 0.5% bupivacaine + 0.1 mg fentanyl (B+F group)
Study: 8765865
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml 0.5% bupivacaine + 2 ml saline (Bup group)
Study: 30925948
Drug: Small-dose ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose ropivacaine hydrochloride (1 mL) combined with fentanyl (10 µg)
Study: 30925948
Drug: Large-dose ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose ropivacaine hydrochloride (1.5 mL)
Study: 30925948
Drug: Small-dose ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose ropivacaine hydrochloride combined with fentanyl
Study: 28493623
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg over 8 days)
Study: 22446565
Drug: Valacyclovir (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (1.5 g twice daily for 18 weeks)
Study: 20017356
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg daily for 30 days
Study: 20017356
Drug: Nimesulide 100
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100 mg BID for 30 days
Study: 8689337
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone followed by oral cefixime
Study: 6366811
Drug: Ordinary metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary metoprolol tablets (100 mg twice daily)
Study: 6366811
Drug: Sustained-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release metoprolol tablets (200 mg once daily)
Study: 24418366
Drug: Intervention (depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (depression care management with treatment adherence support and interpersonal psychotherapy if desired)
Study: 16260510
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (daily oral conjugated estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Study: 9988782
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose nutritional formula (Myer's Cocktail)
Study: 9988782
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose nutritional I/V
Study: 30851166
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (esomeprazole 40 mg, amoxicillin 1 g for 5 days, followed by esomeprazole 40 mg, clarithromycin 500 mg, and tinidazole 500 mg for 5 days)
Study: 30851166
Drug: 14-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day sequential therapy (esomeprazole 40 mg, amoxicillin 1 g for 7 days, followed by esomeprazole 40 mg, clarithromycin 500 mg, and tinidazole 500 mg for 7 days)
Study: 25329822
Drug: Fentanyl (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (100 μg)
Study: 21846796
Drug: Methyl selenocysteine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl selenocysteine, single-dose, pharmacokinetics
Study: 21846796
Drug: Selenomethionine, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenomethionine, 200 μg per day
Study: 21846796
Drug: Selenized yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenized yeast (NPC agent)
Study: 2560284
Drug: Enalapril (E),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (E), 10 mg/day for four weeks
Study: 26743288
Drug: Different oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different oral hygiene maintenance programs
Study: 26743288
Drug: Fixed orthodontic
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed orthodontic treatment with proper oral hygiene
Study: 30203746
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of zoledronic acid
Study: 16835383
Drug: CHOP followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP followed by high-dose therapy with ASCT (4 cycles)
Study: 16835383
Drug: CHOP followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP followed by high-dose therapy with ASCT
Study: 16835383
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with complete response at end of induction therapy
Study: 12697371
Drug: 1200 mg/day
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/day elemental calcium and 800 IU/day vitamin D(3) supplementation
Study: 11007833
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) at 85 IU/kg b.w. (HHR)
Study: 11007833
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) at 45 IU/kg b.w. (LHR)
Study: 9068336
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction followed by a standard propofol infusion
Study: 8437256
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (2-tablet quinolone treatment)
Study: 8437256
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment in premenopausal group
Study: 8437256
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment in postmenopausal group
Study: 3093022
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms 24R,25(OH)2D3 daily
Study: 3093022
Drug: 24R,25(OH)2D3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24R,25(OH)2D3 treatment
Study: 26862746
Drug: Low-abrasivity gel-to-foam
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-abrasivity gel-to-foam fluoride toothpaste (1,450 ppm NaF)
Study: 26862746
Drug: Medium-abrasivity gel-to-foam
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-abrasivity gel-to-foam fluoride toothpaste (1,450 ppm NaF)
Study: 24815910
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, and 70 mg/day
Study: 15878099
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation (AF) - 60.8 Gy in 32 fractions over 26 days, two fractions per day (1.8 Gy and 2.0 Gy) with a 6h gap, 1 week treatment gap after first 12 fractions.
Study: 11955466
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) - 10-20 treatments, 10 Hz, 110% motor threshold applied to the left dorsolateral prefrontal cortex for a total of 10,000-20,000 stimulations
Study: 11955466
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) - 4-12 treatments
Study: 7634871
Drug: Theophylline 3
Normalized name: theophylline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 3 mg/kg
Study: 7634871
Drug: Theophylline 6
Normalized name: theophylline 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 6 mg/kg
Study: 7634871
Drug: Theophylline 0
Normalized name: theophylline 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 0 mg/kg (Control)
Study: 2203382
Drug: Another procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another procaine preparation
Study: 911591
Drug: 2% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% plain lignocaine 20 ml
Study: 911591
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine 20 ml with adrenaline 1:200,000
Study: 25724021
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection without acupuncture
Study: 22299093
Drug: Three different
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different types of implants from three different manufacturers
Study: 22299093
Drug: Implants loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants loaded after 8 weeks
Study: 20555044
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 microg every 6 h for a maximum of four doses
Study: 20555044
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 microg every 12 h for a maximum of four doses
Study: 19040018
Drug: 1.0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/m2 bortezomib combined with dexamethasone
Study: 19040018
Drug: 1.3 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg/m2 bortezomib combined with dexamethasone
Study: 12154491
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment for athlete's foot
Study: 12154491
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment for athlete's foot
Study: 8916060
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg once daily for 2 weeks
Study: 8916060
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg twice daily for 2 weeks
Study: 6356969
Drug: Intramuscular fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular fentanyl
Study: 27480401
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (OMP) 400 mg/day
Study: 22932279
Drug: Folate intake
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate intake from FA-containing prenatal supplement (750 μg/d) plus natural food folate (400 μg/d)
Study: 12060478
Drug: Product containing
Normalized name: Product containing plant agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product containing active ingredients to restore barrier function and modulate inflammatory response, applied twice a day for one month prior to UVA irradiation.
Study: 2187822
Drug: d‐fenfluramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐fenfluramine (15 mg)
Study: 6138044
Drug: midazolam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam (15 mg)
Study: 31294589
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group behavioral treatment (IGBT)
Study: 28637047
Drug: Endobronchial valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial valve treatment (EBV)
Study: 27488272
Drug: Three-phase multifaceted
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-phase multifaceted intervention including academic detailing with a pharmacist, GP-led medicines reviews, web-based pharmaceutical treatment algorithms, and tailored patient information leaflets
Study: 27488272
Drug: GP-led medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GP-led medicines reviews with patients present
Study: 10689295
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nefopam as Acupan(R) administered as a 5‐ or 20‐min intravenous infusion
Study: 10689295
Drug: Vehicle (control)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control) administered to subjects during the control phase
Study: 30121630
Drug: Spironolactone treatment
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone treatment for 9 months
Study: 30121630
Drug: Spironolactone treatment
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone treatment for 9 months (within-person analysis)
Study: 25637909
Drug: 10-session individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-session individual and group cognitive behavior therapy (CBT) for anxiety disorders
Study: 19430060
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iron polymaltose complex (IPC), n=59
Study: 19430060
Drug: Oral Ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ferrous sulfate (FS), n=59
Study: 15060518
Drug: L-DOPA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (200 mg) and benserazide (50 mg) administered 1 hour before sleeping for 30 days
Study: 9215056
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with 0.4% oxybuprocaine
Study: 27406638
Drug: Cotrimoxazole (CTX)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole (CTX) prophylaxis administered from 6 weeks of age
Study: 24076367
Drug: Bronchodilator tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator tiotropium (18 mcg)
Study: 24076367
Drug: Bronchodilator salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator salmeterol (50 mcg)
Study: 24076367
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg once daily for 2 weeks)
Study: 24076367
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (for 2 weeks)
Study: 24076367
Drug: Post-treatment (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (4 weeks after cessation of prednisolone)
Study: 24076367
Drug: Dyspnea VAS
Normalized name: VP/VA COPOLYMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyspnea VAS score after 2 weeks of treatment
Study: 23592936
Drug: FDTV 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDTV 2 mg/180 mg once per day
Study: 23592936
Drug: T 2
Normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T 2 mg once per day
Study: 18417461
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg once daily plus a calorie-restricted diet
Study: 18417461
Drug: Rimonabant 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 5 mg once daily plus a calorie-restricted diet
Study: 18417461
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg and 5 mg
Study: 15917157
Drug: Intranasal 17beta‐oestradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17beta‐oestradiol, 300 microg daily
Study: 15917157
Drug: Transdermal matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal matrix patch 17beta‐oestradiol, 50 microg/day
Study: 11029964
Drug: Basal feed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal feed + rapeseed oil (60 g/kg feed)
Study: 11029964
Drug: Basal feed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal feed + rapeseed oil (60 g/kg feed) + vitamin E (200 mg/kg)
Study: 24859430
Drug: Regular supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular supervised aquatic exercise (low-intensity aerobic aquatic exercise, twice a week for 10 years)
Study: 22730113
Drug: Dexamethasone with
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone with thalidomide (200 mg daily) for 12 months
Study: 12031363
Drug: Adjunctive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment with oral nifedipine and deflazacort
Study: 9822140
Drug: Combined thiazide
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined thiazide and potassium-sparing diuretic
Study: 7521907
Drug: Filgrastim (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (both doses combined)
Study: 31196813
Drug: Solithromycin 1000
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solithromycin 1000 mg (single dose oral)
Study: 31196813
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg (intramuscular) plus Azithromycin 1000 mg (oral)
Study: 21130937
Drug: Treatment interventions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interventions for complicated grief
Study: 9184363
Drug: iv meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv meropenem 1 g tds
Study: 9184363
Drug: iv cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv cefotaxime 1 g tds and iv metronidazole 500 mg tds
Study: 1351538
Drug: Prolonged chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged chemotherapy (with tamoxifen for postmenopausal patients)
Study: 3114351
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal nitroglycerin (16 h/day)
Study: 3114351
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal nitroglycerin (24 h/day)
Study: 28436092
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (supplement (+) group)
Study: 28436092
Drug: No creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No creatine supplementation (supplement (-) group)
Study: 21983766
Drug: nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5 mg
Study: 16931217
Drug: Once-daily sevelamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily sevelamer dosing
Study: 16931217
Drug: Thrice-daily sevelamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily sevelamer dosing
Study: 11110230
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/100 mg
Study: 11110230
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg/16 mg
Study: 11110230
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/50 mg plus HCTZ 12.5 mg
Study: 11110230
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg plus HCTZ 12.5 mg
Study: 8882193
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Study: 8882193
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Study: 1407887
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined hormone replacement therapy (various regimens)
Study: 1407887
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (10 mg)
Study: 1407887
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (1 mg)
Study: 4061431
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment with follow-up interviews
Study: 29781302
Drug: Additional Family-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional Family-Based Treatment (FBT)
Study: 29781302
Drug: Alternate Treatment
Normalized name: Target Alternate Site Lancet 26G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate Treatment Group
Study: 20522617
Drug: Atomoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine treatment after 1 week
Study: 20522617
Drug: Atomoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine treatment after 2 to 3 weeks
Study: 9385104
Drug: Proposed tests
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed tests for treatment effect on time to disease under informative censoring assumptions.
Study: 9385104
Drug: Semiparametric estimators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiparametric estimators for treatment effect.
Study: 224125
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate preparation
Study: 31970563
Drug: 1.23% acidulated
Normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% acidulated fluoride gel and CO2 laser (0.066 J/cm2)
Study: 24614832
Drug: Microwave diathermy
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave diathermy (MD) treatment and exercises
Study: 22458574
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors (UFH + GPI)
Study: 17687635
Drug: High-dose pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pravastatin (40 mg/day)
Study: 17687635
Drug: Low-dose pravastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pravastatin (10 mg) + ezetimibe (10 mg)
Study: 7599345
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g bid sucralfate gel
Study: 7599345
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g qid sucralfate suspension
Study: 3334108
Drug: Naproxen 375
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375 mg twice daily